Terms: = Leukemia AND HNRNPA2B1, ENSG00000122566, SNRPB1, RNPA2, HNRPB1, HNRPA2, HNRNPB1, HNRNPA2, 3181
11 results:
1. RNA N6-methyladenosine reader IGF2BP3 promotes acute myeloid leukemia progression by controlling stabilization of EPOR mRNA.
Fan J; Zhuang M; Fan W; Hou M
PeerJ; 2023; 11():e15706. PubMed ID: 37663284
[TBL] [Abstract] [Full Text] [Related]
2. N6-methyladenosine in hematological malignancies: a concise review.
Wang WJ; Xu TT; Bao J
Curr Opin Hematol; 2023 Jan; 30(1):4-13. PubMed ID: 36165537
[TBL] [Abstract] [Full Text] [Related]
3. [Establishment and validation of prognosis predictive model using m
Xu JR; Yang DH; Long GF; Sun H; Chen HB
Zhonghua Yu Fang Yi Xue Za Zhi; 2021 Aug; 55(8):983-989. PubMed ID: 34445837
[No Abstract] [Full Text] [Related]
4. Does Mixed Chimerism After Allogeneic Hematopoietic Cell Transplantation in Pediatric Patients With Fanconi Anemia Impact on Outcome?
Ayas M; Siddiqui K; Al-Jefri A; Al-Ahmari A; Ghemlas I; Al-Saedi H; Al-Anazi A; Khan S; El-Solh H; Al-Seraihi A
Transplant Cell Ther; 2021 Mar; 27(3):257.e1-257.e6. PubMed ID: 33781527
[TBL] [Abstract] [Full Text] [Related]
5. Highly favourable outcomes with peptide receptor radionuclide therapy (PRRT) for metastatic rectal neuroendocrine neoplasia (NEN).
Kong G; Grozinsky-Glasberg S; Hofman MS; Akhurst T; Meirovitz A; Maimon O; Krausz Y; Godefroy J; Michael M; Gross DJ; Hicks RJ
Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):718-727. PubMed ID: 30343432
[TBL] [Abstract] [Full Text] [Related]
6. SRSF2 mutations drive oncogenesis by activating a global program of aberrant alternative splicing in hematopoietic cells.
Liang Y; Tebaldi T; Rejeski K; Joshi P; Stefani G; Taylor A; Song Y; Vasic R; Maziarz J; Balasubramanian K; Ardasheva A; Ding A; Quattrone A; Halene S
Leukemia; 2018 Dec; 32(12):2659-2671. PubMed ID: 29858584
[TBL] [Abstract] [Full Text] [Related]
7. Integrated molecular analysis of adult T cell leukemia/lymphoma.
Kataoka K; Nagata Y; Kitanaka A; Shiraishi Y; Shimamura T; Yasunaga J; Totoki Y; Chiba K; Sato-Otsubo A; Nagae G; Ishii R; Muto S; Kotani S; Watatani Y; Takeda J; Sanada M; Tanaka H; Suzuki H; Sato Y; Shiozawa Y; Yoshizato T; Yoshida K; Makishima H; Iwanaga M; Ma G; Nosaka K; Hishizawa M; Itonaga H; Imaizumi Y; Munakata W; Ogasawara H; Sato T; Sasai K; Muramoto K; Penova M; Kawaguchi T; Nakamura H; Hama N; Shide K; Kubuki Y; Hidaka T; Kameda T; Nakamaki T; Ishiyama K; Miyawaki S; Yoon SS; Tobinai K; Miyazaki Y; Takaori-Kondo A; Matsuda F; Takeuchi K; Nureki O; Aburatani H; Watanabe T; Shibata T; Matsuoka M; Miyano S; Shimoda K; Ogawa S
Nat Genet; 2015 Nov; 47(11):1304-15. PubMed ID: 26437031
[TBL] [Abstract] [Full Text] [Related]
8. Proteomics of acute myeloid leukaemia: Cytogenetic risk groups differ specifically in their proteome, interactome and post-translational protein modifications.
Balkhi MY; Trivedi AK; Geletu M; Christopeit M; Bohlander SK; Behre HM; Behre G
Oncogene; 2006 Nov; 25(53):7041-58. PubMed ID: 16732326
[TBL] [Abstract] [Full Text] [Related]
9. p210BCR/ABL-induced alteration of pre-mRNA splicing in primary human CD34+ hematopoietic progenitor cells.
Salesse S; Dylla SJ; Verfaillie CM
Leukemia; 2004 Apr; 18(4):727-33. PubMed ID: 14961028
[TBL] [Abstract] [Full Text] [Related]
10. Weekly, high-dose paclitaxel in advanced lung carcinoma: a phase II study with pharmacokinetics by the Cancer and leukemia Group B.
Akerley W; Herndon JE; Egorin MJ; Lyss AP; Kindler HL; Savarese DM; Sherman CA; Rosen DM; Hollis D; Ratain MJ; Green MR
Cancer; 2003 May; 97(10):2480-6. PubMed ID: 12733147
[TBL] [Abstract] [Full Text] [Related]
11. Mutant p53 protein, Bcl-2/Bax ratios and apoptosis in paediatric acute lymphoblastic leukaemia.
Srinivas G; Kusumakumary P; Nair MK; Panicker KR; Pillai MR
J Cancer Res Clin Oncol; 2000 Jan; 126(1):62-7. PubMed ID: 10641752
[TBL] [Abstract] [Full Text] [Related]
